Diagnosis and Management of Fibrotic Interstitial Lung Diseases
Copyright © 2021 Elsevier Inc. All rights reserved..
Nonidiopathic pulmonary fibrosis (non-IPF) progressive fibrotic interstitial lung diseases (PF-ILDs) are a heterogeneous group of ILDs, often challenging to diagnose, although an accurate diagnosis has significant implications for both treatment and prognosis. A subgroup of these patients experiences progressive deterioration in lung function, physical performance, and quality of life after conventional therapy. Risk factors for ILD progression include older age, lower baseline pulmonary function, and a usual interstitial pneumonia pattern. Management of non-IPF P-ILD is both pharmacologic and nonpharmacologic. Antifibrotic drugs, originally approved for IPF, have been considered in patients with other fibrotic ILD subtypes, with favorable results in clinical trials.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Clinics in chest medicine - 42(2021), 2 vom: 26. Juni, Seite 321-335 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Collins, Bridget F [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 19.07.2021 Date Revised 19.07.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ccm.2021.03.008 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM325737215 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM325737215 | ||
| 003 | DE-627 | ||
| 005 | 20231225193055.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ccm.2021.03.008 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1085.xml |
| 035 | |a (DE-627)NLM325737215 | ||
| 035 | |a (NLM)34024407 | ||
| 035 | |a (PII)S0272-5231(21)00035-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Collins, Bridget F |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Diagnosis and Management of Fibrotic Interstitial Lung Diseases |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.07.2021 | ||
| 500 | |a Date Revised 19.07.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Elsevier Inc. All rights reserved. | ||
| 520 | |a Nonidiopathic pulmonary fibrosis (non-IPF) progressive fibrotic interstitial lung diseases (PF-ILDs) are a heterogeneous group of ILDs, often challenging to diagnose, although an accurate diagnosis has significant implications for both treatment and prognosis. A subgroup of these patients experiences progressive deterioration in lung function, physical performance, and quality of life after conventional therapy. Risk factors for ILD progression include older age, lower baseline pulmonary function, and a usual interstitial pneumonia pattern. Management of non-IPF P-ILD is both pharmacologic and nonpharmacologic. Antifibrotic drugs, originally approved for IPF, have been considered in patients with other fibrotic ILD subtypes, with favorable results in clinical trials | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Antifibrotic treatment | |
| 650 | 4 | |a Connective tissue disease-interstitial lung disease | |
| 650 | 4 | |a Fibrotic hypersensitivity pneumonitis | |
| 650 | 4 | |a Idiopathic pulmonary fibrosis | |
| 650 | 4 | |a Nintedanib | |
| 650 | 4 | |a Pirfenidone | |
| 650 | 4 | |a Progressive fibrotic interstitial lung disease | |
| 650 | 4 | |a Unclassifiable interstitial lung disease | |
| 700 | 1 | |a Luppi, Fabrizio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinics in chest medicine |d 1991 |g 42(2021), 2 vom: 26. Juni, Seite 321-335 |w (DE-627)NLM012973599 |x 1557-8216 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2021 |g number:2 |g day:26 |g month:06 |g pages:321-335 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ccm.2021.03.008 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2021 |e 2 |b 26 |c 06 |h 321-335 | ||